Takeda Pharmaceutical (TSE:4502) agreed a multi-year collaboration with the Indonesian Government to develop the country's plasma collection and biopharmaceutical manufacturing ecosystem. The company also reported Phase 3 data for its TYK2 inhibitor zasocitinib in plaque psoriasis, with trial results showing consistent and high skin clearance rates in difficult to treat patients. For investors following large global drug companies, Takeda Pharmaceutical sits at the intersection of specialty...
Thalia Therapeutics (LSE:THAT) is strengthening its position in the RNA therapeutics sector through the proposed acquisition of Sanmirna Therapeutics and an oversubscribed £2. 75 million fundraising, supporting its transition into a clinical-stage biotechnology company.
Investors talking about TRML also mention
What share of all stock conversation is about TRML?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% 0 | 0% 0 | 0% +0 |
Of the messages about TRML that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 95.86% +26.63 | ||
| Bearish | — | — | — | 4.14% -26.63 |
Of the messages about TRML that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Analysts | — | — | — | 5.65% | ||
| Announcements | — | — | — | 10.73% | ||
| Controversies | — | — | — | 0.38% | ||
| Earnings | — | — | — | 0.13% | ||
| Macro | — | — | — | 82.88% | ||
| Technical Analysis | — | — | — | 0.23% |
Of the messages about TRML, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 0% | 0% | 0% | 22.02% | ||
| Newcomers | 100% | 100% | 100% | 77.98% |